We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Non‐Invasive Prenatal Diagnosis of Spinal Muscular Atrophy Validated

By LabMedica International staff writers
Posted on 08 Oct 2019
The discovery of cell‐free DNA (cfDNA) in maternal plasma has enhanced the development of non‐invasive prenatal testing (NIPT). More...
Although NIPT for fetal aneuploidies has already been clinically applied, non‐invasive prenatal diagnosis for many single‐gene disorders remains on the developing stage.

Droplet digital PCR is a technology with high sensitivity, specificity, and accuracy to detect and analyze low-abundance nucleic acids. Its high resolution is guaranteed by millions of oil droplets generated per test. Utilizing digital PCR, the feasibility of non‐invasive prenatal diagnosis (NIPD) for fetal monogenic disorders has been proved in several studies analyzing cfDNA.

Medical Geneticists at the Central South University (Changsha, China) recruited pregnant women seeking Spinal Muscular Atrophy (SMA) prenatal diagnosis on 16 ~ 22 weeks of gestation for a study. All of the pregnancies had undergone non‐invasive prenatal screening for fetal aneuploidies by next‐generation sequencing (NGS).

The scientists extracted cell‐free DNA from maternal plasma using the QIAamp Circulating Nucleic Acid Kit and the concentrations of cfDNA samples were tested on Qubit. Amniotic fluid was obtained by amniocentesis, from which fetal genomic DNA was extracted by the phenol‐chloroform method. RainDrop droplet digital PCR was performed following standard protocols. SMN1/SMN2 copy numbers of all participants and fetuses were quantified by the multiplex ligation‐dependent probe amplification (MLPA) analysis using SALSA MLPA Kit.

The team reported that the concordance rate with the results of MLPA testing of amniocyte DNA was 94.12% in one test set and 90% in another set of participants. For all tests with a classifiable result, the percent of agreement with the results of MLPA testing of amniocyte DNA was up to 100% (25/25). The authors concluded that they had developed a direct, rapid, and low‐cost technique, which has a potential to be utilized for first‐trimester non‐invasive prenatal diagnosis and screening for spinal muscular atrophy with considerable reliability and feasibility. The study was published on September 25, 2019, in the Journal of Clinical Laboratory Analysis.

Related Links:
Central South University


New
Gold Member
Automatic Hematology Analyzer
DH-800 Series
Collection and Transport System
PurSafe Plus®
New
Gold Member
Hybrid Pipette
SWITCH
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.